retatrutide mechanism triple agonist gip glp-1 glucagon retatrutide Retatrutide: The "Triple G" Peptide That Could Rival Bariatric Surgery (And Why You Shouldn't Wait) Retatrutide vs Tirzepatide Compared |

It distinguishes itself from similar peptides such as Tirzepatide in Semaglutide because it goes beyond one or two mechanisms of action

Growth is supported by physician oversight, reimbursement schemes, and adherence protocols in regulated health systems

Projected retatrutide timeline (based on these patterns) Phase 3 trials began: 2024 (TRIUMPH program) Expected FDA submission: 2026-2027 Expected FDA approval: 2027-2028 Expected commercial availability: 2028 Expected stable widespread availability: 2029-2030 (assuming manufacturing ramp-up and shortage resolution) Key lesson from prior launches Demand for GLP-1 medications has consistently exceeded manufacturer projections

GLP-1 agonists reduce appetite and slow gastric emptying, which can lead to lower blood sugar levels, especially when combined with other glucose-lowering agents

Many users have reported noticeable differences in their appetite control and digestion after a few weeks of use

It is important to note that Hers does not accept insurance and instead operates on a subscription model